Company Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib.
Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2000 |
| IPO Date | Aug 1, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | James E. Dentzer |
Contact Details
Address: 128 Spring Street, Building C, Suite 500 Lexington, Massachusetts 02421 United States | |
| Phone | 617-503-6500 |
| Website | curis.com |
Stock Details
| Ticker Symbol | CRIS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001108205 |
| CUSIP Number | 231269200 |
| ISIN Number | US2312693094 |
| Employer ID | 04-3505116 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| James E. Dentzer | President, Chief Executive Officer, Secretary, Treasurer and Director |
| Diantha Duvall C.P.A., M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Mark W. Noel | Vice President of Technology Management and Intellectual Property |
| Elif McDonald | Vice President of Investor Relations and Corporate Communications |
| Dr. Reinhard Wilhelm von Roemeling M.D. | Senior Vice President of Clinical Development |
| Dr. Jonathan B. Zung Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 12, 2024 | EFFECT | Notice of Effectiveness |
| Apr 10, 2024 | ARS | Filing |
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |